400例儿童皮肤血管异常疗效分析

Analysis of therapeutic efficacy and etiology of hemangioma in 400 children with cutaneous vascular anomalies

目的 探讨低体重儿与血管瘤发生的关系及染料激光单用和联合药物皮损内注射治疗皮肤血管异常的疗效分析.方法 对209例婴儿血管瘤患儿和100例正常儿童自身健康情况及母孕期情况进行问卷调查分析.脉冲染料激光治疗毛细血管瘤、微静脉畸形、蜘蛛痣、化脓性肉芽肿的疗效分析.脉冲染料激光联合药物皮损内注射治疗混合性血管瘤进行临床疗效分析.结果 209例婴儿血管瘤患儿低体重儿占33.49%,正常对照组低体重儿占9%.两组比较差异有统计学意义（u=4.621,P＜0.05）.脉冲染料激光治疗仪治疗毛细血管瘤有效率达到83.69%、治疗微静脉畸形有效率达到92.59%、治疗蜘蛛痣有效率达到100%、治疗化脓性肉芽肿有效率达到50%.脉冲染料激光联合药物皮损内注射治疗混合性血管瘤有效率达到95.59%.结论 低体重儿与血管瘤的发生关系密切.脉冲染料激光治疗毛细血管瘤、微静脉畸形、蜘蛛痣疗效显著.脉冲染料激光联合药物皮损内注射治疗混合性血管瘤疗效更显著.

GUO Yan-ping（Department of Dermatology,Harbin Children＇s Hospital,Harbin 150010,China） JIANG Hai-yan（Department of Dermatology,Harbin ChildrObjective To study the relationship between low birth weight and hemangioma, as well as the efficacy of dye laser alone and in combination with intralesional drugs in the treatment of cutaneous vascular anomalies. Methods A questionaire was designed and delivered to assess the health status of 209 children with hemangioma and 100 normal control children, as well as the situation of their mothers during pregnancy.Pulsed dye laser was utilized to treat capillary hemangioma, venular malformation, spider angioma and pyogenic granuloma, and pulsed dye laser plus intralesional drugs to manage mixed hemangioma, followed by evaluation of therapeutic efficacy. Results Low birth weight babies amounted to 33.49% in 209 children with hemangioma and 9% in normal controls （u = 4.621, P 〈 0.05）. The effective rate of pulsed dye laser was 83.69% for capillary hemangioma, 92.59% for venular malformation, 100% for spider angioma and 50% for pyogenic granuloma. An effective rate of 95.59% was observed for pulsed dye laser plus intralesional drugs in the treatment of mixed hemangioma. Conclusions Low birth weight has a close relationship with the development of hemangioma. A favorable efficacy has been observed for pulsed dye laser in the treatment of capillary hemangioma, venular malformation and spider angioma, and for pulsed dye laser plus intralesional drugs in the treatment of mixed hemangioma.